AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and ...

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...